PROTEOME SCIENCES plc ("Proteome Sciences" or the "Company") PRESS RELEASE Issue of Equity, Directors' Dealings and Total Voting Rights The Company has issued and allotted, subject to admission, 1,258,124 new ordinary shares of 1p
each ("the Shares") following the exercise of
options by Christopher Pearce, Chief Executive Officer, and James Malthouse, Finance Director.
The details of the options exercised are as follows: Name Date of exercise No. of options exercised Exercise price
Christopher Pearce 9 April 2008 450,000 37p
Christopher Pearce 9 April 2008 433,124 45p
James Malthouse 9 April 2008 375,000 37p
Following the exercise of the options, Christopher Pearce holds 6,538,075 ordinary shares,
representing 4.93 per cent of the issued share
capital. James Malthouse holds 625,000 shares, representing 0.47 per cent of the issued share
capital.The Shares will rank equally with the existing ordinary shares of the Company. Application has
been made for the Shares to be admitted to
AIM. Trading is expected to commence on AIM on 16 April 2008 ("Admission").For the purposes of the Financial Services Authority's Disclosure and Transparency Rules,
following Admission the total number of ordinary
shares of Proteome Sciences in issue will be 132,723,571 with each share holding one voting
right. The Company does not hold any ordinary
shares in Treasury. Therefore, the total number of ordinary shares with voting rights will be
132,723,571.
The above figure of 132,723,571 ordinary shares may be used by shareholders in the Company as
the denominator for the calculations by which
they will determine if they are required to notify their interest in, or a change in their
interest in, the share capital of the Company.
Ends
Proteome Sciences plc
Christopher Pearce James Malthouse Chief Executive Officer Finance Director christopher.pearce@proteomics.com james.malthouse@proteomics.com
Tel: +44 (0)1932 865065 Nominated Adviser Landsbanki Securities (UK) Limited Gareth Price / Thilo Hoffman Tel: +44 (0)20 7426 9000 END
|